Skip to content

Tailored Smoking Cessation Intervention in Promoting Sexual and Gender Minority Smokers to Quit Smoking

Tailored or Non-Tailored Smoking Cessation Intervention for Sexual and Gender Minorities

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03669120
Enrollment
46
Registered
2018-09-13
Start date
2018-08-10
Completion date
2020-03-25
Last updated
2020-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoker, Current Every Day Smoker

Brief summary

This trial studies how well tailored smoking cessation intervention works in promoting sexual and gender minority smokers to quit smoking. A program that is specifically designed for the lesbian, gay, bisexual, and transgender community may affect these participants differently than a traditional approach.

Detailed description

PRIMARY OBJECTIVES: I. To test the feasibility of two different approaches for smoking cessation (print materials developed for smoking cessation among the mainstream population versus \[vs.\] an individualized text based approach) among 60 lesbian, gay, bisexual, and transgender (LGBT) smokers. SECONDARY OBJECTIVES: I. To assess the levels of helpfulness, appropriateness, and perceived difficulty of the above mentioned cessation approaches among 60 LGBT smokers. EXPLORATORY OBJECTIVES: I. To test the smoking abstinence rates of two different individualized intensive cessation approaches (mainstream vs. individually-tailored) among 60 LGBT smokers. OUTLINE: Participants are randomized to 1 of 2 arms. ARM I: Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of nicotine replacement therapy (NRT) in the form of nicotine patches, and intensive print materials to promote smoking cessation. ARM II: Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months. After completion of study, participants are followed up at 3 and 6 months.

Interventions

OTHERInformational Intervention

Receive advice to quit smoking and materials to promote smoking cessation

BEHAVIORALTelephone-Based Intervention

Receive individualized text based messages

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Male or female owning a cell phone with a reachable contact number * Self-identified as LGBT individual, regardless human immunodeficiency virus (HIV) serologic status * Smoked at least 100 cigarettes in lifetime * Currently smoking at least 5 cigarettes a day, on average * Willing to set a quit smoking date within a week of the enrollment * English speaking

Exclusion criteria

* Expired carbon monoxide (CO) levels below 7 ppm * Positive history of a medical condition that precludes use of the nicotine patch (e.g., recent myocardial infarction, significant skin disorder, previous severe adverse reaction to nicotine patch, pregnant or breast feeding, assessed with our standard protocol for determining NRT eligibility) * Current use of NRT or other smoking cessation medications (e.g., varenicline or bupropion) * Pregnant or nursing * Enrolled in another smoking cessation program * Partner enrolled on current study

Design outcomes

Primary

MeasureTime frameDescription
Computing recruitment rateAt baselineWill be summarized using descriptive statistics such as the mean, standard deviation, median, interquartile range, and frequency where appropriate. Confidence intervals of 90% for the participating rates at baseline and retention rates at 3- and 6- follow-up will be provided.
Retention ratesAt 3 and 6 monthsWill be summarized using descriptive statistics such as the mean, standard deviation, median, interquartile range, and frequency where appropriate. Confidence intervals of 90% for the participating rates at baseline and retention rates at 3- and 6- follow-up will be provided.

Secondary

MeasureTime frameDescription
Perceived difficultyUp to 6 monthsWill be measured by asking: How easy was it to view the text messages? (Likert scale from 0=Not at all easy to 4=Very easy) How easy was it to respond to the text messages? (Likert scale from 0=Not at all easy to 4=Very easy). Will use t-test to compare between arms.
AppropriatenessUp to 6 monthsWill be measured by asking: Regarding the number of text messages received per day, did you think that there were: (Likert scale from 0=Too many to 2=Not enough). Will use t-test to compare between arms.
Levels of helpfulnessUp to 6 monthsWill be measured by asking: Were the text messages helpful in your attempt to quit smoking cigarettes? (Likert scale from 0= Not at all helpful to 4=Very helpful). Will use t-test to compare between arms.

Other

MeasureTime frameDescription
Point prevalence abstinenceUp to 6 monthsSeven day smoking abstinence along with negative saliva cotinine will be the primary definition of smoking abstinence for this study. Important covariates that will be used to adjust for potential baseline differences include level of education, biological sex, marital status, gender identity, race, working status, income, years smoking, smoking initiation, use of other tobacco products, and living with other household members who smoke.
Salivary cotinine assessed by NicAlert testUp to 6 monthsImportant covariates that will be used to adjust for potential baseline differences include level of education, biological sex, marital status, gender identity, race, working status, income, years smoking, smoking initiation, use of other tobacco products, and living with other household members who smoke.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026